Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2016

Open Access 01-12-2016 | Research article

Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection

Authors: Daniar K. Osmonov, Alexey V. Aksenov, David Trick, Carsten M. Naumann, Moritz F. Hamann, Amr Abou Faddan, Klaus-Peter Jünemann

Published in: BMC Urology | Issue 1/2016

Login to get access

Abstract

Background

The aim was to evaluate cancer-specific survival (CSS) and overall survival (OS) in patients with prostate cancer (PCa) recurrence who underwent salvage extended pelvic lymph node dissection (ePLND), taking into consideration pre- and postoperative androgen deprivation therapy (ADT).

Methods

Salvage ePLND was performed in a cohort of 54 patients with PCa recurrence, and data from 45 patients were analyzed. The indications for salvage ePLND were biochemical recurrence (BCR) of PCa and suspect findings on 11C-choline PET/CT. PSA-level, biochemical response (BR), duration of biochemical recurrence freedom (BCRF), number of metastases, OS and CSS were analyzed retrospectively.

Results

The average follow-up was 42.7 ± 20.8 months. Thirty-three patients (73.3 %, 95 % CI: 60.5–83.6 %) achieved BCRF during follow-up. The mean BCRF-period was 31.4 ± 19.7 months. CSS and OS were both 91.7 % ± 4.8 % (3-year survival) and 80.6 ± 8.6 % (5-year survival). Twenty-four patients (53.3 %, 95 % CI: 40.0–66.3 %) with castration-resistant PCa (CRPC) responded again to ADT after salvage ePLND.

Conclusions

Salvage ePLND for selected patients with BCR and clinically recurrent nodal disease can achieve an immediate complete PSA response (i. e. BCRF) in nearly half of the patients. Patients with CRPC responded again to ADT after ePLND. Multicenter prospective studies with a control group are needed.
Literature
1.
2.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.CrossRefPubMed
3.
Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013;190:441–9.CrossRefPubMed
4.
Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol. 2014;66:479–86.CrossRefPubMed
5.
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.CrossRefPubMed
6.
Sciarra A, Cattarino S, Gentilucci A, Alfarone A, Innocenzi M, Gentile V, et al. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery. Urol Oncol. 2013;31:607–14.CrossRefPubMed
7.
Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol. 2015;193(4):1226–31.CrossRefPubMed
8.
Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. Anticancer Res. 2014;34:6265–9.PubMed
9.
Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, Drendel V, et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol. 2012;188:2190–7.CrossRefPubMed
10.
Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C] choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935–43.CrossRefPubMed
11.
Suardi N, Briganti A, Salonia A, Rigatti P. Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence. Curr Opin Urol. 2011;21:237–40.CrossRefPubMed
12.
Stenzl A. Salvage lymph node dissection in recurrent prostate cancer patients. Eur Urol. 2011;60:944–5.CrossRefPubMed
13.
14.
Osmonov DK, Aksenov AV, Naumann CM, Hamann MF, Jünemann K-P. Kiel template of salvage extended pelvic lymph node dissection in patients with prostate cancer recurrence. Eur Urol Suppl. 2015;14/2:e449.CrossRef
15.
DK Osmonov, AV Aksenov, CA Jilg, W Schultze-Seeman, CM Naumann, MF Hamann, K Bothe, KP Jünemann. Salvage lymphadenectomy in patients with prostate cancer recurrence: A review. Urologe A. 2015 Dec 19. [Epub ahead of print] German.
16.
Naumann CM, Macquarrie A, Van Der Horst C, Hamann MF, Al-Najar A, Kaufmann S, et al. Histological detection of minimal metastatic disease in inguinal non-sentinel lymph nodes in penile cancer. Anticancer Res. 2010;30:467–71.PubMed
17.
Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, et al. ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol. 2011;24:39–47.CrossRefPubMed
18.
Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748–57.CrossRefPubMedPubMedCentral
19.
Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, et al. Utility of [(11)C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol. 2014;32:38. e9-38.e16.PubMed
20.
Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97.CrossRefPubMed
21.
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.CrossRefPubMed
22.
Sanz G, Robles JE, Giménez M, Arocena J, Sánchez D, Rodriguez-Rubio F, et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int. 1999;84:1028–31.CrossRefPubMed
23.
Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001;57:108–11.CrossRefPubMed
24.
Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–9.CrossRefPubMed
25.
Osmonov DK, Heimann D, Janßen I, Aksenov A, Kalz A, Juenemann KP. Sensitivity and specificity of PET/CT regarding the detection of lymph node metastases in prostate cancer recurrence. Springerplus. 2014;3:340.CrossRefPubMedPubMedCentral
Metadata
Title
Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection
Authors
Daniar K. Osmonov
Alexey V. Aksenov
David Trick
Carsten M. Naumann
Moritz F. Hamann
Amr Abou Faddan
Klaus-Peter Jünemann
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2016
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-016-0173-3

Other articles of this Issue 1/2016

BMC Urology 1/2016 Go to the issue

Research article

Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia

Research article

Flexible and rigid ureteroscopy in outpatient surgery

Research article

TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer

Research article

Coffee and caffeine intake and risk of urinary incontinence: a meta-analysis of observational studies

Research article

Comparison of the complications of traditional 12 cores transrectal prostate biopsy with image fusion guided transperineal prostate biopsy

Research article

Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned